Dyax Corp. Receives Orphan Drug Designation From The FDA For DX-2930 In Hereditary Angioedema
BURLINGTON, Mass.--(BUSINESS WIRE)--Dyax Corp. (NASDAQ:DYAX) today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to its drug candidate DX-2930, its fully human monoclonal antibody inhibitor of plasma kallikrein, for use in the treatment of hereditary angioedema (HAE).
Help employers find you! Check out all the jobs and post your resume.